{"id":2022,"date":"2017-12-31T00:00:45","date_gmt":"2017-12-30T17:00:45","guid":{"rendered":"https:\/\/www.hivnat.org\/en\/?p=2022"},"modified":"2022-03-30T10:06:04","modified_gmt":"2022-03-30T03:06:04","slug":"a-phase-iii-randomized-double-blind-study-to-evaluate-the-safety-and-efficacy-of-elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-versus-elvitegravir-cobicistat-emtricitabine-tenofovir-di","status":"publish","type":"post","link":"https:\/\/www.hivnat.org\/en\/studies\/2022\/","title":{"rendered":"A phase 3, randomized, double-blind study to evaluate the safety and efficacy of Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide versus Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir disoproxil fumarate in HIV-1 positive, antiretroviral treatment-na\u00efve adults"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Randomized, Double-Blind, multicenter, active-controlled study to evaluate the Safety and Efficacy of Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide Versus Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Disoproxil Fumarate in achieving HIV-1 RNA &lt; 50 copies\/mL at Week 48 as defined by the FDA snapshot analysis in HIV-1 infected subjects. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>\t\t\t\tRandomized, Double-Blind, multicenter, active-controlled study to evaluate the Safety and Efficacy of Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide Versus Elvitegravir\/Cobicistat\/Emtricitabine\/ Tenofovir Disoproxil Fumarate in achieving HIV-1 RNA < 50 copies\/mL at Week 48 as defined by the FDA snapshot analysis in HIV-1 infected subjects. \t\t\n<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-2022","post","type-post","status-publish","format-standard","hentry","category-studies"],"_links":{"self":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/2022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/comments?post=2022"}],"version-history":[{"count":1,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/2022\/revisions"}],"predecessor-version":[{"id":3341,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/2022\/revisions\/3341"}],"wp:attachment":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/media?parent=2022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/categories?post=2022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/tags?post=2022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}